A new $50.5M Series C round has landed for Trevi Therapeutics, Inc., the New Haven-based biopharmaceutical company focused on chronic cough treatments. The funding will advance its lead investigational therapy, Haduvio™.
Trevi is developing Haduvio (oral nalbuphine extended-release) for conditions like idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Notably, it's the first and only investigational therapy to show a statistically significant reduction in cough frequency in clinical trials for IPF chronic cough and RCC patients, acting as a kappa agonist and a mu antagonist.
